Sep 27, 2021 03:49 PM (GMT+8) · EqualOcean
Zhou Siyuan, deputy director of the drug review center of the State Food and drug administration, said that the drug review center should change from the review of generic drugs to the review of drug innovation. Adhere to patient-centered, clinical value oriented, and encourage drug innovation and development. Zhou Siyuan believes that in the future, the drug trial center should focus on clinical value and promote drug innovation to a higher level. We will continue to strengthen efforts to encourage drug innovation, especially on the basis of laws and regulations, strengthen communication and exchange in the process of clinical value oriented drug innovation, especially based on high-standard and high-quality drug R & D data.

This text is a result of machine translation.